Suh Young-jin, head of the Breast Thyroid Gland Cancer Center at the Catholic University of Korea St. Vincent's Hospital, shares the latest treatment strategy for patients with hormone receptor (HR) positive, HER2 negative breast cancer.
{"Image XResolution": "300", "Image YResolution": "300", "Image ResolutionUnit": "Pixels/Inch", "Image Software": "paint.net 4.1", "Image ExifOffset": "104", "EXIF DateTimeOriginal": "2021:04:22 15:03:40", "EXIF DateTimeDigitized": "2021:04:22 15:03:40", "EXIF SubSecTimeOriginal": "00", "EXIF SubSecTimeDigitized": "00"}